AstraZeneca PLC is 194.1x more valuable than MBX Biosciences, Inc. by market capitalization ($286.27 B vs $1.48 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MBX | AZN |
|---|---|---|
| Market cap | $1.48 B | $286.27 B |
| US-listed rank | #2324 | #45 |
| Net income (latest FY) | -$87.00M | - |
| SEC filings | 198 | 1,004 |
AstraZeneca PLC is 194.1x more valuable than MBX Biosciences, Inc. by market capitalization ($286.27 B vs $1.48 B).
Full pages: MBX Biosciences, Inc. and AstraZeneca PLC, or browse the full rankings.